← Back to Search

MAPK Pathway Inhibitor

DCC-3084 for Cancer

Phase 1 & 2
Recruiting
Research Sponsored by Deciphera Pharmaceuticals LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up start of therapy to death due to any cause (estimated up to 36 months)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called DCC-3084 on its own or with other cancer treatments in people with advanced cancers. It will first focus on patients with solid tumors and may include other

Who is the study for?
This trial is for adults with advanced cancers, including lung cancer, melanoma, and pancreatic cancer that are linked to specific genetic changes in the MAPK pathway. Participants should have a type of tumor or condition like RASopathy or Neurofibromatosis.
What is being tested?
The study is testing DCC-3084, either alone or with other treatments. It's divided into two parts: first finding the right dose (Dose Escalation), then giving it to more people at this dose (Dose Expansion) to see how well it works and its safety.
What are the potential side effects?
Possible side effects of DCC-3084 may include typical reactions seen with cancer therapies such as nausea, fatigue, skin issues, liver function changes but will be detailed as the trial progresses through phases.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~start of therapy to death due to any cause (estimated up to 36 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and start of therapy to death due to any cause (estimated up to 36 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with Dose-limiting Toxicities (DLTs) (ModA Part 1)
Objective Response Rate (ORR) (ModA Part 2)
Secondary study objectives
ORR (ModA Part 1)
Overall Survival (OS) (ModA Part 1 and 2)
Pharmacokinetics (PK): Maximum observed plasma drug concentration (Cmax) (ModA Part 1 and 2)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: DCC-3084 Module A Expansion Phase (ModA Part 2)Experimental Treatment1 Intervention
Participants will receive DCC-3084 in ModA Part 2, Expansion Phase.
Group II: DCC-3084 Module A Escalation Phase (ModA Part 1)Experimental Treatment1 Intervention
Participants will receive DCC-3084 in ModA Part 1, Escalation Phase.

Find a Location

Who is running the clinical trial?

Deciphera Pharmaceuticals LLCLead Sponsor
16 Previous Clinical Trials
1,861 Total Patients Enrolled
Deciphera Pharmaceuticals, LLCLead Sponsor
18 Previous Clinical Trials
2,017 Total Patients Enrolled
~93 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top